Clinical Trial Update: Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)

View source ↗

Summary

A post-marketing surveillance study evaluating Ventavis (iloprost) in Chinese patients with pulmonary arterial hypertension has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ventavis (iloprost)

Snippet

Sponsor: Bayer | Conditions: Primary Hypertension | Status: COMPLETED